Elan (ELN -3.1%) slips on a downgrade to Neutral on valuation at UBS, noting that Bapineuzumab's...

|About: Elan Corporation, plc (ELN)|By:, SA News Editor

Elan (ELN -3.1%) slips on a downgrade to Neutral on valuation at UBS, noting that Bapineuzumab's economic potential may be lower than expected.